The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2020Pre-clinical Development of Compounds that Modulate Mitophagy through Regulation of the Mitochondrial GTPase Miro1
Study Rationale:
Evidence indicates that mitochondrial dysfunction is a significant contributor to Parkinson’s disease, with the majority of patients exhibiting a shared defect in the processing of... -
Alpha-Synuclein Imaging, 2020Alpha-Synuclein PET Tracer Discovery
Study Rationale:
The discovery of new treatments for Parkinson’s disease has been slowed by the time it takes to answer the question “did a drug work” in a clinical trial. Tests that can assess... -
Therapeutic Pipeline Program, 2020Pregnenolone for the Treatment of L-DOPA-induced Dyskinesia in Parkinson's disease
Study Rationale:
Neurosteroids are substances that occur naturally in the brain and help regulate and modulate the activity of brain cells. In previous studies, the investigators demonstrated that... -
Access to Data and Biospecimens, 2020Development of a Biomarker Platform for Parkinson’s Disease Using Patient-derived Cells
Study Rationale:
Inadequate understanding of how Parkinson's disease develops is a major roadblock in developing effective therapeutics and methods to diagnose the disease earlier. This project... -
Improved Biomarkers and Clinical Outcome Measures, 2020Assessment of Brain Tau Burden in Parkinson's Disease with or without a LRRK2 Mutation using [18F]MK-6240 PET Imaging
Study Rationale:
The precise mechanisms of cellular damage in Parkinson's disease remain unclear. Research has shown that abnormal forms of the protein alpha-synuclein accumulates in brain cells in... -
Therapeutic Pipeline Program, 2020Target Validation Studies for the Discovery of Novel Small Molecule Therapeutics with the Potential to Modify Disease Outcome by Inhibiting Bacterial Amyloid Protein-induced Alpha-synuclein Aggregation and Associated Neuronal Toxicity
Study Rationale:
Patients with Parkinson’s disease frequently report serious gastrointestinal (GI) symptoms, most commonly constipation, which are not well treated with currently available medicine...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.